CTAs keep buying Treasuries, gold longs face stop-loss risk: BofA
Topline Capital Partners (WA:CPAP), LP, a significant shareholder in Paysign, Inc. (NASDAQ:PAYS), a $163 million market cap fintech company with 28% revenue growth over the last twelve months, recently executed a series of transactions involving the sale of common stock. According to a filing with the Securities and Exchange Commission, Topline sold a total of 274,982 shares over two days.
On January 13, Topline sold 154,982 shares at a price of $3.06 per share. The following day, an additional 120,000 shares were sold at $3.24 per share. The total value of these transactions amounted to $863,044. InvestingPro analysis shows the stock has gained nearly 9% in the past week, despite trading below its Fair Value.
Following these sales, Topline Capital Partners retains ownership of 5,336,146 shares in Paysign. The transactions were reported by Collin McBirney, Managing Member of Topline Capital Management, LLC, the general partner of Topline Capital Partners, LP. InvestingPro subscribers can access additional insights, including 7 more ProTips and a comprehensive research report on PAYS, helping investors make more informed decisions.
In other recent news, Paysign Inc. reported a notable increase in its financial performance. The company announced a 23% year-over-year revenue growth to $15.3 million and a 20.6% rise in adjusted EBITDA to $2.8 million in its third-quarter earnings call. The report also showed a 219% surge in its patient affordability segment, with 66 active programs, and a 3.4% growth in plasma donor compensation revenue to $11.4 million.
Despite challenges in the plasma business and ongoing legal expenses, Paysign maintains a positive outlook, expecting revenues between $56.5 million and $58.5 million and a net income guidance of $3 million to $3.5 million for the remainder of the year. The company also revealed plans to expand its program offerings, including a new partnership with a leading pharmaceutical company.
These are recent developments that highlight Paysign's robust performance and strategic focus on patient affordability, which has positioned it favorably against competitors. The company's unique technology and open book pricing model have also been highlighted as key competitive advantages.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.